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1EXECUTIVE SUMMARY FEBRUARY 2020
• Patient and user safety with regards to medical 
devices is paramount. This should be prioritised 
in situations where there are competing 
considerations such as “attractiveness of the UK” 
as to the conduct of clinical trials and supply of 
medicines and medical devices.
• The existing regulatory framework for medicines 
and medical devices has become complex 
and unwieldly. Legislation which consolidates 
regulation on each these areas (separately) is 
needed. A requirement to introduce this should be 
included in the Bill.
• The Medicines and Medical Devices Bill confers 
on the Secretary of State an extensive range 
of powers to make regulations pertaining to 
medicines, clinical trials, and medical devices. 
This is necessary in the short-term to facilitate 
alignment with those parts of EU law which are to 
be implemented post-transition; notably the EU 
Clinical Trials Regulation and the In Vitro Devices 
Regulation. However, the on-going use of delegated 
powers in this area should be time-limited.
Introduction
The Medicines and Medical Devices Bill had its first 
reading in the House of Commons on 13 February 
2020. The Bill proposes a legislative programme for 
the regulation of medicines and medical devices in the 
UK at the end of the EU exit transition period, currently 
31 December 2020. It is imperative that the Bill 
provides for high standards of safety and is forward-
looking so as to capture the fast pace of innovation in 
these areas.
Some aspects of the Bill indicate the Government 
is moving in the right direction. For example, the Bill 
introduces much needed consolidated and expanded 
enforcement provisions, including criminal and civil 
provisions for breach of obligations relating to medical 
devices. Additionally, the Bill recognises the need to be 
responsive and flexible with regards to medicines and 
medical device regulation.
However, there are aspects of the Bill which are less 
positive. It does not appropriately address patients’ 
and users’ safety. There is an overreliance on the 
use of delegated powers to achieve its aims. And, 
as it stands, it will increase, rather than reduce the 
complexity of the existing regulatory framework.
Patient and user safety should be prioritised
The Bill contains the requirement that the Secretary 
of State must have regard to the safety and availability 
of medicines and medical devices (Parts 1 and 3), as 
well as the” attractiveness of the relevant part of the 
United Kingdom” as place in which to conduct clinical 
trials or supply medicines (Part 1) and place in which 
to develop or supply medical devices (Part 3). 
Whilst recognising the need for the UK to remain 
competitive, patient and user safety must be 
paramount. Recent scandals such as those concerning 
DePuy metal-on-metal hips and PIP breast implants 
have demonstrated the need for strong regulatory 
oversight. Currently there is no definition in the Bill as 
to what constitutes “the attractiveness of the relevant 
part of the United Kingdom”. 
The attractiveness clauses should either (a) be 
removed entirely from the Bill, or (b) a clear statutory 
definition of attractiveness should be included in 
the Bill, along with a further clause requiring the 
appropriate authority to prioritise safety whenever the 
three elements need to be balanced.  
Northern Ireland and potential regulatory 
divergence
In relation to medicines, the Bill refers to Northern 
Ireland separately from England, Wales, and Scotland.  
Medicines are a devolved power while devices are 
not. Clauses 1(3) and 1(4) confer the power to 
enact separate regulations with regards to Northern 
Ireland, with the prospect of a  separate weighing 
of the ‘attractiveness’ criterion. This raises the 
important question of whether in the future, without 
the requirement to implement EU law, there could be 
2heightened regulatory divergence between Northern 
Ireland and the rest of the UK in the area of medicines 
regulation.
The need for consolidated legislation
The existing medical device regulatory framework has 
over time become complex and unwieldly. It consists 
of:
• The Medical Devices Regulations 2002 
(SI/2002/618), implementing three different 
EU Directives (Directive 90/385/EEC, Directive 
93/42/EEC, and Directive 98/79/EEC).
• The EU Regulation on Medical Devices (Regulation 
(EU) 217/745), which will be fully implemented 
by 26 May 2020.  This repeals and replaces the 
Directives. As this will occur during the EU exit 
transition period, the Regulation will automatically 
become part of UK law.
In addition:
• The EU Regulation on In-Vitro Diagnostic Medical 
Devices 2017/746 will not be fully implemented 
until 26 May 2022 and so will not automatically 
become part of UK law during the EU exit transition 
period. 
• The Medical Devices (Amendment etc.) (EU Exit) 
Regulations 2019 come into force at the end of 
the EU exit transition period unless alternative 
provisions are made. These amend the Medical 
Devices Regulations 2002 to mirror key elements 
contained in EU Regulation on Medical Devices 
2017/745 and the EU Regulation on In-Vitro 
Diagnostic Medical Devices 2017/746 (in order to 
maintain good regulatory alignment between the 
UK and EU, as well as between different parts of 
the UK’s own regulatory framework).
The Bill represents an opportunity for the Government 
to address the range of legislation incorporated 
in statutory instruments and to provide a more 
streamlined legislative approach. This should be 
done by 2022 to coincide with the need for regulatory 
alignment with the In Vitro Diagnostic Regulation.
Time-limit the use of delegated powers
The Bill confers the Secretary for State with an 
extensive range of delegated powers to make 
regulations about medicines and medical devices. 
This includes: powers with regards to manufacture, 
marketing, and supply; falsified medicines; 
clinical trials; fees, information, and offences; and 
emergencies. In effect, this covers the majority of 
areas where regulation might be required.
It is important that the medicines and medical devices 
regulatory framework is appropriately responsive 
and flexible in order to take account of (a) the EU exit 
transition period and (b) future technological and other 
changes. However, delegated powers should not be 
used indefinitely. Doing so risks inadequate scrutiny 
and oversight of major regulatory objectives and 
changes. 
A recent report of the House of Lords Select Committee 
on the Constitution (The Legislative Process: The 
Delegation of Powers) recommended that whilst 
delegated powers are appropriate ‘to make provision 
for minor and technical matters . . ., [i]t is essential 
that primary legislation is used to legislate for policy 
and other major objectives.’ 
To deal with this, the Bill should include a clause 
which time-limits the provisions in this proposed 
legislation and requires the Government to introduce 
comprehensive primary legislation. In line with the 
recommendation on the need for consolidated 
legislation above, this should be done by 2022.
Summary of recommendations
Parliament should:
• Ensure that patient and user safety is prioritised 
over competing considerations. Clauses 1(2), 8(2), 
and 12(2) should be amended to reflect this. 
• Clarification should be provided as to any future 
intention regarding possible regulatory divergence 
regarding medicines between Northern Ireland and 
the rest of the UK. 
• The life of the subsequent Act, and thus the 
extensive use of delegated powers contained 
therein, should be time-limited. New sub-clauses 
reflecting this should be inserted into Clauses 1, 8, 
and 12 of the Bill.
• Separate pieces of primary legislation for 
medicines and medical devices should be 
introduced by 2022. This will enable the 
successive amendments to be integrated and 
consolidated, making the regulatory framework 
more stream-lined and easier to understand.
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